OZANIMOD (Zeposia®)
Clinical Indication
Adults with active disease as part of relapsing-remitting Multiple Sclerosis.
Comments
Not yet reviewed
Date of classification
December 2020
Grey
Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.
- New medicines, devices, appliances.
- New indication of existing medicine.
- New NICE TA which has not been reviewed.
- Not been requested for review by either TAS/LPT MMC.